US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Inside information, profit warning: Optomed receives a large order in the US and increases its full year outlook

Optomed Plc      Inside Information                        11 November 2024 at 21.00, Helsinki Inside information, profit warning: Optomed receives a large order in the US and increases its full year outlook Optomed has received a EUR 1.5 million order and increases its full year 2024 outlook. The received order is from a US screening service provider. The order is traditional device capex transaction and does not include AI service or a recurring revenue component. The device stock levels for other products than Optomed Aurora AEYE are temporarily low after the delivery, and it

Optomed Plc: Interim Report, January – September 2024

Optomed Plc Stock Exchange Release 7 November 2024 at 9.00, Helsinki Optomed Plc: Interim Report, January – September 2024 July – September 2024 · Revenue decreased by 26.3 percent to EUR 3.1 (4.2) million against a strong comparison period of Q3-2023 that was supported by a Device segment delivery to Spain worth approximately EUR 0.8 million and a large delivery to China · Devices segment revenue decreased by 55.5 percent to EUR 0.8 (1.8) million. Without the Q3 2023  one-time deal in Spain, the revenue would have decreased EUR 0.2 million. · Software segment revenue

Optomed’s January-September 2024 interim report will be published on 7 November 2024

Optomed Plc Press Release 31 October 2024 at 9.00, Helsinki Optomed’s January-September 2024 interim report will be published on 7 November 2024 Optomed will publish its January-September 2024 interim report on 7 November 2024 approximately at 9.00 EET.   A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EET/10.00 CET. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.   The participants are requested to register for the call in advance

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed Plc Stock Exchange Release 30 September 2024 at 8.40, Helsinki Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Danske Bank A/S (“Notifier”). According to the notification, the total holdings in Optomed shares and votes held the by DanskeBank A/S is 5.08 per cent of all of the registered shares in Optomed on 26 September 2024.   The total number

Inside information, profit warning: Optomed decreases its full year outlook

Optomed Plc Inside Information 25 September 2024 at 20.00, Helsinki Inside information, profit warning: Optomed decreases its full year outlook Optomed decreases its full year 2024 outlook. The Company now expects its full year 2024 revenue to decrease from 2023. In the Software Segment, certain key deliveries have been postponed until 2025, and in the Devices Segment, the traditional distributor and OEM sales have been slower than estimated earlier. Optomed estimates that in the US revenue will grow strongly and grow in China compared to 2023. The Q3-2023 comparison period was

Composition of Optomed’s Nomination Board

Optomed Plc Stock Exchange Release 11 September 2024 at 9.00, Helsinki Composition of Optomed’s Nomination Board According to Optomed’s shareholder register of 2nd of September 2024, the shareholders represented in the shareholders’ Nomination Board are OP-Rahastoyhtiö Oy (OP funds), SP-Rahastoyhtiö Oy (SP Funds) and Danske Invest Rahastoyhtiö Oy (Danske Funds). These shareholders have appointed the following persons to the Nomination Board:   · Vesa Vanha-Honko, OP funds · Olli Tuuri, SP funds · Ville Kivipelto, Danske Invest Petri Salonen, Chairman of Optomed’s

Optomed Plc - Managers' transactions - Myllylä

Optomed Plc - Managers' Transactions – 12 August 2024 at 12.00 EET Optomed Plc - Managers' transactions - Myllylä ____________________________________________ Person subject to the notification requirement Name: Markku Myllylä Position: Other senior manager Issuer: Optomed Oyj LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 74101/4/4 ____________________________________________ Transaction date: 2024-08-09 Outside a trading venue Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT Name of

Change in Optomed’s holding of treasury shares

Optomed Plc Stock Exchange Release 9 August 2024 at 18.30, Helsinki Change in Optomed’s holding of treasury shares Optomed has conveyed 8,744 treasury shares to the members of the Board of Directors as a part of the Board members' annual remuneration in accordance with the decision of the Annual General Meeting 2024. The amount of shares is based on the monthly remuneration decided by the Annual General Meeting and Optomed's value weighted average share price between 1 August and 7 August 2024.   A total of 310,500 of shares have been subscribed for under the Company’s stock option

Optomed Plc - Managers' transactions - Lee

Optomed Plc - Managers' Transactions – 9 August 2024 at 18.30 EET Optomed Plc - Managers' transactions - Lee ____________________________________________ Person subject to the notification requirement Name: Lee, Ty Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20240809145959_55 ____________________________________________ Transaction date: 2024-08-09 Venue not applicable Instrument type: SHARE ISIN: FI4000410881 Nature of the

Optomed Plc - Managers' transactions - Tauriainen

Optomed Plc - Managers' Transactions – 9 August 2024 at 18.30 EET Optomed Plc - Managers' transactions - Tauriainen ____________________________________________ Person subject to the notification requirement Name: Tauriainen, Reijo Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20240809145959_58 ____________________________________________ Transaction date: 2024-08-09 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Optomed Plc - Managers' transactions - Piila

Optomed Plc - Managers' Transactions – 9 August 2024 at 18.30 EET Optomed Plc - Managers' transactions - Piila ____________________________________________ Person subject to the notification requirement Name: Piila, Laura Position: Other senior manager Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20240808113323_41 ____________________________________________ Transaction date: 2024-08-07 Venue not applicable Instrument type: SHARE ISIN: FI4000410881 Nature of the

Optomed Plc - Managers' transactions - Calarco

Optomed Plc - Managers' Transactions – 9 August 2024 at 18.30 EET Optomed Plc - Managers' transactions - Calarco ____________________________________________ Person subject to the notification requirement Name: Calarco, Catherine Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20240809145958_54 ____________________________________________ Transaction date: 2024-08-09 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Optomed Plc - Managers' transactions - Mäkinen

Optomed Plc - Managers' Transactions – 9 August 2024 at 18.30 EET Optomed Plc - Managers' transactions - Mäkinen ____________________________________________ Person subject to the notification requirement Name: Mäkinen, Seppo Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20240809145959_56 ____________________________________________ Transaction date: 2024-08-09 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Optomed Plc - Managers' transactions - Salonen

Optomed Plc - Managers' Transactions – 9 August 2024 at 18.30 EET Optomed Plc - Managers' transactions - Salonen ____________________________________________ Person subject to the notification requirement Name: Salonen, Petri Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20240809145959_57 ____________________________________________ Transaction date: 2024-08-09 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Optomed Plc - Managers' transactions - Tenstam

Optomed Plc - Managers' Transactions – 9 August 2024 at 18.30 EET Optomed Plc - Managers' transactions - Tenstam ____________________________________________ Person subject to the notification requirement Name: Tenstam, Anna Position: Member of the Board/Deputy member Issuer: Optomed Plc LEI: 7437009IVYWGEE4S7B77 Notification type: INITIAL NOTIFICATION Reference number: 7437009IVYWGEE4S7B77_20240809145959_59 ____________________________________________ Transaction date: 2024-08-09 Venue not applicable Instrument type: SHARE ISIN: FI4000410881

Optomed’s financial reporting in 2025

Optomed Plc Stock Exchange Release 8 August 2024 at 9.05, Helsinki Optomed’s financial reporting in 2025 Optomed Plc will release its Financial Statement Bulletin, Half-Year Financial Report and Interim Reports in 2025 as follows: · Financial Statement Bulletin for 1 January – 31 December 2024, 13 February 2025 · Interim Report for 1 January – 31 March 2025, 6 May 2025 · Half-Year Financial Report for 1 January – 30 June 2025, 7 August 2025 · Interim Report for 1 January – 30 September 2025, 6 November 2025 Annual Report 2024, which includes the company’s financial

Optomed Plc: Half-year Report, January – June 2024

Optomed Plc Stock Exchange Release 8 August 2024 at 9.00, Helsinki Optomed Plc: Half-year Report, January – June 2024 April – June 2024   · Revenue decreased by 6.4 percent to EUR 3.5 (3.7) million. · Devices segment revenue decreased by 15.7 percent to EUR 1.1 (1.3) million. · Software segment revenue decreased by 1.6 percent to EUR 2.4 (2.5) million. · Adjusted EBITDA amounted to EUR -0.8 (-0.5) million corresponding to -22.9 (-12.4) percent of revenue. and EBITDA was EUR -1.2 (-0.5) million corresponding to -33.8 (-12.4) percent of revenue and · EBITDA was

Optomed’s January-June 2024 half year report will be published on 8 August 2024

Optomed Plc Press Release 1 August 2024 at 9.00, Helsinki Optomed’s January-June 2024 half year report will be published on 8 August 2024 Optomed will publish its January-June 2024 half-year report on 8 August 2024 approximately at 9.00 EET.   A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EET/10.00 CET. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.   The participants are requested to register for the call in advance by email to

Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed Plc Stock Exchange Release 2 July 2024 at 10.45, Helsinki Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings Optomed Plc (“Optomed” or the “Company”) has received a notification in accordance with the Chapter 9, Section 5 of the Finnish Securities Markets Act (as amended, the “SMA”) from Sp Rahastoyhtiö Oy (“Notifier”). According to the notification, the total holdings in Optomed shares and votes held the investment funds of Sp-Rahastoyhtiö (Säästöpankki Pienyhtiöt, Säästöpankki Kotimaaa) is 6.51 per cent of all of the registered

New shares subscribed for in Optomed Plc’s directed share issue have been registered in the Finnish Trade Register

OPTOMED PLC STOCK EXCHANGE RELEASE 1 July 2024, at 8:30 a.m. EEST   New shares subscribed for in Optomed Plc’s directed share issue have been registered in the Finnish Trade Register A total of 1,500,000 new shares subscribed for in Optomed Plc’s directed share issue have been registered into the Finnish Trade Register today, on 1 July 2024. After the registration of the new shares, the company will have 19,630,397 shares in total of which 353,973 shares in treasury.   The new shares produce the right to dividends and other distribution of assets as well as other shareholder

Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 7.9 million

OPTOMED PLC INSIDE INFORMATION   26 June 2024, at 9.30 p.m. EEST Inside information: Optomed Plc successfully completes directed share issue raising approximately EUR 7.9 million NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. The Board of Directors (the “Board”) of Optomed Plc (“Optomed”

Inside Information: Optomed has signed a shareholder’s agreement with Zhongbao Fund to establish a joint venture in China

Optomed Plc Inside Information  24 June 2024 at 14.00, Helsinki Inside Information: Optomed has signed a shareholder’s agreement with Zhongbao Fund to establish a joint venture in China Optomed has signed a shareholder’s agreement with regards to a joint venture in China with Zhongbao, a Chinese private equity firm based in Shenzhen, China. The firm focuses on growth opportunities, and it invests in a diversified range of industries. Optomed will own 19.9% of the joint venture and Zhongbao 80.1%.   Previously, Optomed has announced in its Q1-2024 report about discussions with

Optomed and Toku Inc. enter a partnership to commercialize AI for Cardiovascular Disease Risk

Optomed Plc Press Release 30 May 2024 at 9.00, Helsinki Optomed and Toku Inc. enter a partnership to commercialize AI for Cardiovascular Disease Risk Optomed has signed a global partnership agreement with US-based artificial intelligence company Toku Inc. Toku specializes in imaging technology and AI and has recently been granted the FDA’s Breakthrough Device designation for its cardiovascular risk detection algorithm, CLAiR. CLAiR has also achieved a CE designation, according to MDR, and a UKCA. Toku also has an AI software called BioAge for assessing a person’s biological age in

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media